Connect with us

Published

on

President-elect Donald Trumps choice to run the sprawling government agency that administers Medicare, Medicaid, and the Affordable Care Act marketplace celebrity doctor Mehmet Oz recently held broad investments in health care, tech, and food companies that would pose significant conflicts of interest. Use Our Content

It can be republished for free.

Ozs holdings, some shared with family, included a stake in UnitedHealth Group worth as much as $600,000, as well as shares of pharmaceutical firms and tech companies with business in the health care sector, such as Amazon. Collectively, Ozs investments total tens of millions of dollars, according to financial disclosures he filed during his failed 2022 run for a Pennsylvania U.S. Senate seat.

Trump said Tuesday he would nominate Oz as administrator of the Centers for Medicare & Medicaid Services. The agencys scope is huge: CMS oversees coverage for more than 160 million Americans, nearly half the population. Medicare alone accounts for approximately $1 trillion in annual spending, with over 67 million enrollees.

UnitedHealth Group is one of the largest health care companies in the nation and arguably the most important business partner of CMS, through which it is the leading provider of commercial health plans available to Medicare beneficiaries.

UnitedHealth also offers managed-care plans under Medicaid, the joint state-federal program for low-income people, and sells plans on government-run marketplaces set up via the Affordable Care Act. Oz also had smaller stakes in CVS Health, which now includes the insurer Aetna, and in the insurer Cigna. Email Sign-Up

Subscribe to KFF Health News' free Weekly Edition. Your Email Address Sign Up

It’s not clear if Oz, a heart surgeon by training, still holds investments in health care companies, or if he would divest his shares or otherwise seek to mitigate conflicts of interest should he be confirmed by the Senate. Reached by phone on Wednesday, he said he was in a Zoom meeting and declined to comment. An assistant did not reply to an email message with detailed questions.

Its obvious that over the years hes cultivated an interest in the pharmaceutical industry and the insurance industry, said Peter Lurie, president of the Center for Science in the Public Interest, a watchdog group. That raises a question of whether he can be trusted to act on behalf of the American people. (The publisher of KFF Health News, David Rousseau, is on the CSPI board.)

Oz used his TikTok page on multiple occasions in November to praise Trump and Robert F. Kennedy Jr., including their efforts to take on the illness-industrial complex, and he slammed so-called experts like the big medical societies for dishing out what he called bad nutritional advice. Ozs positions on health policy have been chameleonic; in 2010, he cut an ad urging Californians to sign up for insurance under President Barack Obamas Affordable Care Act, telling viewers they had a historic opportunity.

Ozs 2022 financial disclosures show that the television star invested a substantial part of his wealth in health care and food firms. Were he confirmed to run CMS, his job would involve interacting with giants of the industry that have contributed to his wealth.

Given the breadth of his investments, it would be difficult for Oz to recuse himself from matters affecting his assets, if he still holds them. He could spend his time in a rocking chair if that happened, Lurie said.

In the past, nominees for government positions with similar potential conflicts of interest have chosen to sell the assets or otherwise divest themselves. For instance, Treasury Secretary Janet Yellen and Attorney General Merrick Garland agreed to divest their holdings in relevant, publicly traded companies when they joined the Biden administration.

Trump, however, declined in his first term to relinquish control of his own companies and other assets while in office, and he isnt expected to do so in his second term. He has not publicly indicated concern about his subordinates financial holdings.

CMS main job is to administer Medicare. About half of new enrollees now choose Medicare Advantage, in which commercial insurers provide their health coverage, instead of the traditional, government-run program, according to an analysis from KFF, a health information nonprofit that includes KFF Health News.

Proponents of Medicare Advantage say the private plans offer more compelling services than the government and better manage the costs of care. Critics note that Medicare Advantage plans have a long history of costing taxpayers more than the traditional program.

UnitedHealth, CVS, and Cigna are all substantial players in the Medicare Advantage market. Its not always a good relationship with the government. The Department of Justice filed a 2017 complaint against UnitedHealth alleging the company used false information to inflate charges to the government. The case is ongoing.

Oz is an enthusiastic proponent of Medicare Advantage. In 2020, he proposed offering Medicare Advantage to all; during his Senate run, he offered a more general pledge to expand those plans. After Trump announced Ozs nomination for CMS, Jeffrey Singer, a senior fellow at the libertarian-leaning Cato Institute, said he was uncertain about Dr. Ozs familiarity with health care financing and economics.

Singer said Ozs Medicare Advantage proposal could require large new taxes perhaps a 20% payroll tax to implement.

Oz has gotten a mixed reception from elsewhere in Washington. Pennsylvania Sen. John Fetterman, the Democrat who defeated Oz in 2022, signaled hed potentially support his appointment to CMS. If Dr. Oz is about protecting and preserving Medicare and Medicaid, Im voting for the dude, he said on the social platform X.

Ozs investments in companies doing business with the federal government dont end with big insurers. He and his family also hold hospital stocks, according to his 2022 disclosure, as well as a stake in Amazon worth as much as nearly $2.4 million. (Candidates for federal office are required to disclose a broad range of values for their holdings, not a specific figure.)

Amazon operates an internet pharmacy, and the company announced in June that its subscription service is available to Medicare enrollees. It also owns a primary care service, One Medical, that accepts Medicare and select Medicare Advantage plans.

Oz was also directly invested in several large pharmaceutical companies and, through investments in venture capital funds, indirectly invested in other biotech and vaccine firms. Big Pharma has been a frequent target of criticism and sometimes conspiracy theories from Trump and his allies. Kennedy, whom Trump has said hell nominate to be Health and Human Services secretary, is a longtime anti-vaccine activist.

During the Biden administration, Congress gave Medicare authority to negotiate with drug companies over their prices. CMS initially selected 10 drugs. Those drugs collectively accounted for $50.5 billion in spending between June 1, 2022, and May 31, 2023, under Medicares Part D prescription drug benefit.

At least four of those 10 medications are manufactured by companies in which Oz held stock, worth as much as about $50,000.

Oz may gain or lose financially from other Trump administration proposals.

For example, as of 2022, Oz held investments worth as much as $6 million in fertility treatment providers. To counter fears that politicians who oppose abortion would ban in vitro fertilization, Trump floated during his campaign making in vitro fertilization treatment free. Its unclear whether the government would pay for the services.

In his TikTok videos from earlier in November, Oz echoed attacks on the food industry by Kennedy and other figures in his Make America Healthy Again movement. They blame processed foods and underregulation of the industry for the poor health of many Americans, concerns shared by many Democrats and more mainstream experts.

But in 2022, Oz owned stakes worthas much as $80,000 in Dominos Pizza, Pepsi, and US Foods, as well as more substantial investments in other parts of the food chain, including cattle; Oz reported investments worth as much as $5.5 million in a farm and livestock, as well as a stake in a dairy-free milk startup. He was also indirectly invested in the restaurant chain Epic Burger.

One of his largest investments was in the Pennsylvania-based convenience store chain Wawa, which sells fast food and all manner of ultra-processed snacks. Oz and his wife reported a stake in the company, beloved by many Pennsylvanians, worth as much as $30 million.

Darius Tahir: DariusT@kff.org, @dariustahir Related Topics Elections Health Industry Insurance Medicare CMS Medicare Advantage Trump Administration Contact Us Submit a Story Tip

Continue Reading

Environment

The legendary Nissan GT-R will reemerge, but Godzilla may look a little different

Published

on

By

The legendary Nissan GT-R will reemerge, but Godzilla may look a little different

Nissan has officially confirmed the icon will be making a comeback. Although Nissan is no longer building GT-R models, CEO Ivan Espinosa said Godzilla will “evolve and reemerge” in the future. Here’s what we know so far.

Nissan confirms the GT-R will evolve and reemerge

It seems like we’ve been talking about the next-gen Nissan GT-R for years now. After the last model rolled off the production line at the automaker’s Tochigi plant in Japan on Tuesday, Nissan’s CEO made it clear that the GT-R will be making a comeback.

After bidding farewell to the R35, Espinosa gave the many GT-R fans worldwide hope, saying, “I want to tell you this isn’t a goodbye to the GT-R forever.”

He added that it’s Nissan’s “goal for the GT-R nameplate to one day make a return.” Although this is the end of the line for the R35, the company remains committed to the GT-R nameplate and wants to “reimagine it for a new generation.”

Advertisement – scroll for more content

According to Espinosa, Nissan doesn’t have any finalized plans yet, but he promised that “the GT-R will evolve and reemerge in the future.”

Nissan-delays-supplier-payments
Nissan’s new N7 electric sedan alongside the GT-R (Source: Dongfeng Nissan)

Nissan says the next Godzilla will ensure the GT-R’s legacy lives on, but will pack even more performance. The big question is, what type of powertrain will it arrive with? Will it be electric? A hybrid? Or, will it still be gas-powered?

At the New York Auto Show in April, Ponz Pandikuthira, Senior Vice President and Chief Planning Officer for Nissan North America, told The Drive that the next GT-R will be a hybrid, rather than an all-electric.

Nissan-GT-R-reemerge-EV
Nissan’s new N7 electric sedan alongside the GT-R (Source: Dongfeng Nissan)

However, Nissan previewed an electric GT-R a few years ago with the Hyper Force EV concept. The electric sports car concept was promoted as a “game-changing hyper EV” with over 1,300 horsepower (1,000 kW).

All that power is expected to come from solid-state batteries. Just last week, Nissan secured a partnership with LiCAP Technologies to produce all-solid-state EV batteries on a mass scale, one of the biggest hurdles to getting the new technology to market.

Nissan-GT-R-solid-state-batteries
Nissan Hyper Force EV concept (Source: Nissan)

Since Nissan aims to launch its first EV powered by solid-state batteries in 2028, we could see the GT-R reemerge as a plug-in hybrid until the technology is ready.

Either way, it will likely be a few years before we see an electrified Godzilla. If it evolves into an EV or hybrid, it remains up in the air for now.

While Nissan says an all-electric GT-R won’t deliver the performance needed to live up to the nameplate, others are proving otherwise. BYD’s first electric supercar, the Yangwang U9, set a new EV speed record this week after hitting nearly 300 mph.

How do you feel about it? Should the GT-R go all-electric? Or will Nissan settle for a hybrid? Drop us a comment below and let us know which one you’d buy.

FTC: We use income earning auto affiliate links. More.

Continue Reading

Sports

Buckeyes’ orders for Sayin: ‘Just win’ vs. Horns

Published

on

By

Buckeyes' orders for Sayin: 'Just win' vs. Horns

COLUMBUS, Ohio — Ohio State coach Ryan Day has one message for freshman quarterback Julian Sayin, who will be making his first career start for the No. 3 Buckeyes against top-ranked Texas on Saturday.

“Just win,” Day said Tuesday. “Find a way to win.”

All eyes will be on Sayin and new Texas starting quarterback Arch Manning in the showdown at Ohio Stadium. It’s a rematch of last year’s College Football Playoff semifinal when both players watched from the sideline as Will Howard and Ohio State eliminated Quinn Ewers and Texas on the way to winning the national championship.

Both Sayin and Manning were five-star recruits coming out of high school. Manning started two games in Austin last season when Ewers suffered an injury; Sayin attempted only 12 passes last year in mop-up duty.

Day said the Buckeyes aren’t putting “crazy expectations” on Sayin, who beat out Lincoln Kienholz for the starting nod in the preseason.

“Take care of the ball. … If you need to throw it away, throw it away,” Day said of his discussions with Sayin heading into Saturday. “Don’t worry about anything else other than winning the game. That’s the most important thing — that’s the job of the quarterback.”

Ohio State will debut eight new starters after losing the bulk of last season’s championship defense to the NFL. Day said facing Manning will pose a “tremendous” challenge for the revamped defense.

“Athletic; a big, strong arm; smart; quick release; accurate — all of the above,” Day said of Manning. “I mean, he checks every box.”

Continue Reading

Sports

Colorado names transfer Salter QB1 for opener

Published

on

By

Colorado names transfer Salter QB1 for opener

Colorado coach Deion Sanders named Kaidon Salter the Buffaloes’ starting quarterback on Tuesday, ahead of the team’s opener Friday against Georgia Tech.

“The kid has a ton of experience, dual threat, can throw the heck out of the ball as well,” said Sanders. “He’s the guy. He’s the guy at this point.”

Salter, who transferred to Colorado after three years as a starter at Liberty, was the presumed starter but had been competing with five-star true freshman Julian Lewis.

“He’s done it before,” said Sanders. “This is not his first time running out the tunnel and getting the start. … I like what he did in the spring, and he’s growing and growing and growing.”

Sanders credited offensive coordinator Pat Shurmur and volunteer assistant coach Byron Leftwich for their work with Salter.

“I defer to those two coaches to allow me to understand what I see as valid,” said Sanders, who added that he is hopeful Lewis will also get game reps.

Salter appeared in two games for Liberty in 2021, before starting most of the team’s games of over the next three years. During that span, he threw for 5,889 yards with 56 touchdowns and 17 interceptions. He also ran for 2,006 yards.

He will replace Shedeur Sanders, who started the past two years for Colorado, before being drafted in the fifth round by the Cleveland Browns.

Continue Reading

Trending